BioRestorative Therapies (BRTX) Q3 2024 earnings summary

Executive summary

• Strong execution across all business areas in Q3 2024, with progress in clinical, commercial, and regulatory programs, including preliminary phase 2 BRTX-100 data for chronic lumbar disc disease (CLDD) and a provisional NYSDOH license for allogeneic tissue processing.

• BRTX-100 is a novel autologous cell therapy targeting low-oxygen, low-blood-flow disc environments, aiming for nonsurgical treatment of painful lumbosacral disc disorders.

• Preliminary blinded data show 70% of first 10 patients at 26 weeks achieved >30% improvement in both pain and function, exceeding FDA efficacy benchmarks.

• No severe adverse events or dose-limiting toxicities observed at current dosing, indicating strong safety profile.

• Presented ThermoStem® metabolic disease platform at IFATS 2024, highlighting potential advantages over GLP-1 obesity drugs and secured a Notice of Allowance for a new Israeli patent.

Financial highlights

• Q3 2024 revenue increased to $233,600 from $30,700 year-over-year, driven by new cosmetic product sales and ongoing royalty revenue.

• Gross profit for Q3 2024 was $215,357, up from $0 in Q3 2023; nine-month gross profit was $332,967, up from $0.

• Net loss for Q3 2024 was $1.1 million, or $0.13 per share, compared to net income of $4.8 million in Q3 2023.

• Ended Q3 2024 with $13.1 million in cash, cash equivalents, and marketable securities, and no outstanding debt.

• Working capital at September 30, 2024 was $8.9 million, up from $8.8 million at year-end 2023.

Outlook and guidance

• Enrollment for the phase 2 BRTX-100 trial is progressing well, with completion expected before end of 2024 and larger patient data sets to be presented in early 2025.

• Considering interim unblinded analysis at 26 weeks in first half of 2025.

• Ongoing discussions for potential licensing of ThermoStem® metabolic IP with a commercial-stage regenerative medicine company.

• Current cash and investments are expected to fund operations for at least 12 months from the reporting date, but additional financing will be required to complete development activities and reach profitability.

• Exploring expansion of BRTX-100 indications to include cervical spine disorders.